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Patients and Methods: Nineteen pts with a median age of 56
years (range 18–70) not eligible for ablative SCT received
Campath-1H 20 mg/m2, ﬂudarabine 25 mg/m2  5 days and
either cyclophosphamide 1 g/m2  2 days (n16 pts), melpha-
lan 140 mg/m2 (n1 pt) or busulfan 0.8 mg/m2  8 doses (n2
pts) followed by G-CSF stimulated peripheral blood (n13) or
unmanipulated bone marrow(n6). GVHD prophylaxis con-
sisted of CSA at least until T60 and mycophenolate mofetil
through T30. DLI was allowed for residual/progressive dis-
ease or mixed chimerism after T60 in absence of GVHD.
Seven pts had a previous autologous transplantation. Ten pts
had myeloid diseases (AML6, CML Ph negative1, CML
accelerated phase1, therapy related MDS1, myeloﬁbro-
sis1); 9 pts lymphoid (HD3, NHD5, PLL1); only 5 pts
were in CR at transplant. Six pts received bone marrow with a
median CD34 cells infused of 3.7  106/kg, and 13 pts pe-
ripheral blood with a median of 4.5  106/kg CD34 cells
infused. Results:19 achieved ANC 0.5  106/L within a
median of 12 days (range 8–16); 2 pts rejected the graft and 1
had autologous reconstitution; 10/19 achieved sustained platelet
engraftment at a median of 16 days (range 7–27). 2/17 pts with
sustained engraftment developed acute GVHD; 7/14 at risk pts
had CMV reactivation; TRM at T100 was 16% (disease pro-
gression in 2 and GVHD in 1). Nine pts received DLI (5 for
persistent mixed chimerism and 4 pts for persistent/progressive
disease). After DLI 5 pts had GVHD limited to skin. Of the pts
with myeloid malignancies 2 pts remain alive in CR at T28,
19 months; of the pts with lymphoid malignancies 2 pts with
HD are alive in CR at T34, 15 months and 2 pts with mantle
cell lymphoma are alive at T19, T13 months. Causes of
death include disease progression in 7 pts, CMV disease in 1 pt,
adenovirus/CMV disease in 1 pt, sepsis in 1 pt and GVHD in 3
pts. Conclusion: These results suggest that this approach is well
tolerated with a low early TRM even in pts with advanced
disease. Longer follow-up and better patient selection are
needed.
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UMBILICAL CORD BLOOD TRANSPLANTS (UCBT). EVALUATION OF
CHIMERISM AND SURVIVAL IN RELATION TO CD34 OR MONONUCLEAR
CELL (MNC) DOSE INFUSED. THE CHILDREN’S MEMORIAL HOSPITAL
(CMH) EXPERIENCE
Merchant, M.1; Olszewski, M.1; Duerst, R.1,2; Huang, W.1; Jacobsohn,
D.1,2; Kletzel, M.1,2 1. Children’s Memorial Hospital, Chicago, IL; 2.
Northwestern University Feinberg School of Medicine, Chicago, IL.
To evaluate chimerism and to determine if cell dose/kg has a
relationship with time to full chimerism in children undergoing
Hematopoietic UCBT unrelated (n85) related (n3) at CMH;
between 1995 and 2004, one hundred and one UCBT were per-
formed at CMH of those 88 meet the study criteria (survive 30
days post transplant) to be evaluable for engraftment and survival.
There were patients (pts) with malignant (n71) and non-malig-
nant (17) diseases with a mean age of 5.0 years (.6–16) and a mean
weight of 20.2 kg (5.6–61). The preparative regimen consisted of
fTBI (1200 cGy) day 8 to 5, VP-16 1000 mg/m2 day 4 and
cyclophosphamide 60 mg/kg/day days 3 to 1. GVHD prophy-
laxis consisted of CSA, short course MTX, ATG (days 1, 3, 5, 7).
Engraftment was deﬁned as the time to reach 95% donor chi-
merism, assessed by either ﬂuorescence in-situ hybridization or
variable number tandem repeats (VNTRs). Cell counts were mea-
sured by the Abbott Cell Dyne counter and the CD34 cells were
quantiﬁed by ﬂow cytometry on a FACS sorter. Pts were divided in
two groups according to cell doses received (
.7 or .7) for
CD34  106/kg and MNC  108/kg cells. Statistical analysis was
made by a non-parametric t test and column statistics (mean 	
SEM and all were at the 95% CI) on (Graph Pad). The overall
engraftment of the 88 patients was 72% (63/88). There was no
difference among the groups in volume infused, malignant or
non-malignant or the status of disease prior to transplant. Pts with
the lower CD34 and MNC cells infused were heavier and showed
a lower incidence of full chimerism and a trend to slower engraft-
ment. There was also a survival difference in favor of the higher
CD34 cell infused group.
Table 1. CD34  106/kg MNC  108/kg
Cell Doses <.7 >.7 p Value <.7 >.7 p Value
Age 6.8  0.8 4.0  3.6 0.002 6.6  0.5 2.2  .45 <0.0001
Weight 25.7  2.4 17.2  1.3 0.0015 24.8  1.6 12.5  1.1 <0.0001
Days to >95%
chimerism 37.3  4.6 30.8  2.9 0.2 34.8  3.3 29.6  3.7 0.3
% achieving full
chimerism 52.9 83.3 0.001 56.8 78.0 0.02
% Overall
survival 44.1 61.6 0.001 53.4 56.6 n/s
Number of
patients 34 54 58 30
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HEMATOPOIETIC CELL TRANSPLANTATION (HCT)-SPECIFIC-COMOR-
BIDITY INDEX: A NEW TOOL FOR RISK ASSESSMENT BEFORE ALLO-
GENEIC HCT
Sorror, M.L.1; Maris, M.B.1,2; Storb, R.F.1,2; Baron, F.1; Sandmaier,
B.M.1,2; Maloney, D.G.1,2; Barry, S.E.1,2 1. Fred Hutchinson Cancer
Research Center; 2. University of Washington, Seattle, WA.
We have reported on the use of Charlson comorbidity index
(CCI) to predict non-relapse mortality (NRM) and overall survival
(OS) for patients (pts) given nonablative or ablative HCT1. How-
ever, the sample size of pts with scores of1, captured by the CCI,
did not exceed 35%. Further, some of comorbidities were rarely
found among pts given HCT. Therefore, we sought to develop an
HCT-speciﬁc-comorbidity index aimed at a) better deﬁning pre-
viously identiﬁed comorbidities, i.e. adding pulmonary functions
tests to pulmonary, liver function tests to hepatic, and ejection
fraction 50% to cardiac comorbidities and b) investigating addi-
tional HCT-related comorbidities. To this end, we retrospectively
reviewed comorbidities of 1055 pts given HCT at our center
between 1997–2003 after nonablative (n294) or ablative (n761)
conditioning. Pts were randomly divided into training (n708) and
validation sets (n347). In the training set, the unadjusted hazard
ratios (HR) for 2-year NRM were calculated for each comorbidity
and then adjusted for other comorbidities, disease risk, and condi-
tioning type. The adjusted HRs were employed as weights for
individual comorbidities. Differences encountered compared to
the original CCI were: a) two new comorbidities were added
(obesity  score 1 and peritransplantation infection  score 2), b)
age 50 years acquired a score of 2, and c) hypertension and
asthma each acquired a score of 1 instead of 0, moderate pulmo-
nary, peptic ulcer, and rheumatologic each acquired a score of 2
instead of 1, valvular heart disease a score of 2 instead of 0, and
severe pulmonary comorbidity a score of 3 instead of 1. In the
training set, HR for NRM for scores 0, 1, 2, 3, 4, 5 were 1, 1.2,
3.5, 6.1, 7.1, and 10.8, respectively. The modiﬁed index was then
validated using the validation set. This index had the advantage of
1) capturing more pts with high scores and 2) distinguishing pts
with low scores who had lower NRM and better OS when com-
pared to the original CCI (Table). Applying the scores to nonab-
lative and ablative pts, respectively, NRM of 5 vs 10% (p0.4) and
OS of 85% vs 75% (p0.1) were seen for scores of 0–1, 17 vs 27%
(p0.04) and 61 vs 59% (p0.2) for scores of 2–3, and 33 vs 54%
(p0.03) and 43 vs 30% (p0.006) for scores of 4. This HCT-
speciﬁc comorbidity index provides a simple, readily applicable and
valid method of estimating NRM and OS among pts given nona-
blative or ablative allogeneic HCT. (1. Sorror et al. Blood. 2004;
104:961.)
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